Yumurtalik kanserinde TNF-β gen polimorfizmin rolü
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
This study explored the relationship between ovarian cancer (OC) risk in Turkish women and polymorphisms in TNF-β (+252A>G), which are known to play a critical role in malignancy development. The study included 47 cases and 45 controls and used RT-PCR for genotyping analysis. Statistical analysis was conducted to compare significant differences between the groups. The outcomes showed that the control group had an AA genotype at 64.4% (29 out of 45), an AG genotype at 35.5% (16 out of 45), and a GG genotype at 0% (0 out of 40). In the ovarian cancer patient group, the AA genotype was at 53.1% (25 out of 47), the AG genotype at 29.7% (14 out of 47), and the GG genotype at 8.5% (4 out of 47). However, no significance was observed when comparing the groups, with a p-value of 0.802. more extensive studies with larger population scales are necessary to determine the exact association. Key words: Ovarian cancer, TNF-β, polymorphism
Author
Shıya Husseın Ibrahım Ibrahım
How to Cite
Shıya Husseın Ibrahım Ibrahım (Master Thesis). Yumurtalik kanserinde TNF-β gen polimorfizmin rolü, 2023, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)